Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.43 |
| ▸ | CKS1B | P61024 | 2/20 | 0.41 |
| ▸ | SKP1 | P63208 | 2/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18502868 | 0.84 | DDB1 (0.53) | GPR119CKS1BSKP1SKP2PTPN11 | |
| SCHEMBL18791108 | 0.84 | CKS1B (0.48) | GPR119CKS1BSKP1SKP2DDB1 | |
| SCHEMBL18502870 | 0.81 | CYP11B2 (0.51) | GPR119CKS1BSKP1SKP2PTPN11 | |
| SCHEMBL18502899 | 0.76 | CYP11B2 (0.52) | GPR119CKS1BSKP1SKP2PTPN11 | |
| SCHEMBL17207602 | 0.75 | GPR119 (0.47) | GPR119CKS1BSKP1SKP2PTPN11 | |
| SCHEMBL18502952 | 0.74 | CYP11B2 (0.52) | GPR119CKS1BSKP1SKP2PTPN11 | |
| SCHEMBL17207585 | 0.73 | CYP11B2 (0.59) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL18502913 | 0.72 | CYP11B2 (0.47) | GPR119CKS1BSKP1SKP2PTPN11 | |
| SCHEMBL17207592 | 0.71 | CYP11B2 (0.59) | GPR119CKS1BSKP1SKP2PTPN11 | |
| SCHEMBL10297496 | 0.69 | GPR119 (0.55) | GPR119CKS1BSKP1SKP2PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| WO-2015163427-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | 田辺三菱製薬株式会社 | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | GPR119 664/4885CKS1B 207/4885SKP1 721/4885 |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | GPR119 664/4885CKS1B 207/4885SKP1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.